Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density

Contraception

Volumn 80, Issue 1, 2009, Pages 7-17

  Kaunitz, Andrew M ^a   Darney, Philip D ^b   Ross, Douglas ^c   Wolter, Kevin D ^d   Speroff, Leon ^e  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bone density; Contraceptive; Depot medroxyprogesterone acetate

Indexed keywords

MEDROXYPROGESTERONE ACETATE;

ABDOMINAL PAIN; ACNE; ADULT; AMENORRHEA; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; INTERMETHOD COMPARISON; LIBIDO; MAJOR CLINICAL STUDY; MOOD CHANGE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SATISFACTION; SIDE EFFECT; SINUSITIS; TREATMENT DURATION; URINARY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ADULT; BONE DENSITY; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; ESTRADIOL; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MEDROXYPROGESTERONE 17-ACETATE; METRORRHAGIA; PATIENT SATISFACTION; PREGNANCY; YOUNG ADULT;

EID: 67349208897     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.02.005     Document Type: Article

References (41)

1. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 68 (2003) 75-87
2. Kaunitz A.M. Depot medroxyprogesterone acetate for contraception. In: Rose B.D. (Ed). UpToDate (2008), UpToDate, Waltham (Mass)
3. Nelson A. Merits of DMPA relative to other reversible contraceptive methods. J Reprod Med 47 9 Suppl (2002) 781-784
4. Jain J., Dutton C., Nicosia A., Wajszczuk C., Bode F.R., and Mishell Jr. D.R. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 70 (2004) 11-18
5. Jain J., Jakimiuk A.J., Bode F.R., Ross D., and Kaunitz A.M. Contraceptive efficacy and safety of DMPA-SC. Contraception 70 (2004) 269-275
6. Prabhakaran S. Self-administration of injectable contraceptives. Contraception 77 (2008) 315-317
7. Lakha F., Henderson C., and Glasier A. The acceptability of self-administration of subcutaneous Depo-Provera. Contraception 72 (2005) 14-18
8. Curtis K.M., and Martins S.L. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 73 (2006) 470-487
9. Hergenroeder A.C. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 126 (1995) 683-689
10. Gbolade B.A. Depo-Provera and bone density. J Fam Plann Reprod Health Care 28 (2002) 7-11
11. Mishell Jr. D.R. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 41 5 Suppl (1996) 381-390
12. Clark M.K., Sowers M., Levy B.T., and Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 75 (2001) 871-877
13. Cummings S.R., Nevitt M.C., Browner W.S., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332 (1995) 767-773
14. Cundy T., Cornish J., Roberts H., and Reid I.R. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol 186 (2002) 978-983
15. Karlsson M.K., Ahlborg H.G., and Karlsson C. Maternity and bone mineral density. Acta Orthop 76 (2005) 2-13
16. Hui S.L., Slemenda C.W., and Johnston Jr. C.C. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81 (1988) 1804-1809
17. Kaunitz A.M., Arias R., and McClung M.R. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 77 (2008) 67-76
18. Cundy T., Cornish J., Evans M.C., Roberts H., and Reid I.R. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 308 (1994) 247-248
19. Petitti D.B., Piaggio G., Mehta S., Cravioto M.C., and Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 95 (2000) 736-744
20. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13 (2002) 581-587
21. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159 (2005) 139-144
22. Clark M.K., Sowers M., Levy B., and Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril 86 (2006) 1466-1474
23. Kaunitz A.M., Miller P.D., Rice V.M., Ross D., and McClung M.R. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 74 (2006) 90-99
24. Rosenberg L., Zhang Y., Constant D., et al. Bone status after cessation of injectable progestin contraceptives. Contraception 76 (2007) 425-431
25. Arias R.D., Jain J.K., Brucker C., Ross D., and Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception 74 (2006) 234-238
26. Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Cundy T., and Reid I.R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49 (1998) 615-618
27. Schwallie P.C., and Assenzo J.R. Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 24 (1973) 331-339
28. Fraser I.S., and Dennerstein G.J. Depo-Provera use in an Australian metropolitan practice. Med J Aust 160 (1994) 553-556
29. Weissman M.M., Bland R.C., Canino G.J., et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276 (1996) 293-299
30. Belsey E.M. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 38 (1988) 181-206
31. Freeman S. Nondaily hormonal contraception: considerations in contraceptive choice and patient counseling. J Am Acad Nurse Pract 16 (2004) 226-238
32. Hubacher D., Goco N., Gonzalez B., and Taylor D. Factors affecting continuation rates of DMPA. Contraception 60 (1999) 345-351
33. Kaunitz A.M. Menstruation: choosing whether ... and when. Contraception 62 (2000) 277-284
34. Nelson A.L. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. J Reprod Med 41 5 Suppl (1996) 391-400
35. American College of Obstetricians and Gynecologists Committee on Practice Bulletins - Gynecology. ACOG practice bulletin no. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107 (2006) 1453-1472
36. World Health Organization. Technical consultation on the effects of hormonal contraception on bone health (2005), World Health Organization, Geneva, Switzerland
37. Black A. Canadian contraception consensus - update on depot medroxyprogesterone acetate (DMPA): Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada. J Obstet Gynaecol Can 28 (2006) 305-313
38. Cromer B.A., Scholes D., Berenson A., Cundy T., Clark M.K., and Kaunitz A.M. Depot medroxyprogesterone acetate and bone mineral density in adolescents - the black box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health 39 (2006) 296-301
39. Royal College of Obstetricians and Gynaecologists National Collaborating Centre for Women's and Children's Health. Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception [commissioned by the National Institute for Health and Clinical Excellence] (2005), Royal College of Obstetricians and Gynaecologists, London, UK
40. Kaunitz A.M. Depo-Provera's black box: time to reconsider?. Contraception 72 (2005) 165-167
41. Paschall S., and Kaunitz A.M. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians. Contraception 78 (2008) 370-376